Literature DB >> 17613287

Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis.

Massimo Papale1, Maria Carmela Pedicillo, Bradley J Thatcher, Salvatore Di Paolo, Lorenzo Lo Muzio, Pantaleo Bufo, Maria Teresa Rocchetti, Marta Centra, Elena Ranieri, Loreto Gesualdo.   

Abstract

The topic of this study is the impact of several pre-analytical and analytical variables on proteomic profiling of human urine by surface enhanced laser desorption/ionization time of flight-mass spectrometry (SELDI-TOF-MS) in healthy subjects. Urine storage at room temperature caused a progressive degradation of proteins, which was prevented by the addition of protease inhibitors only up to 2 h from the collection. The timing of collection over the day had only a minor impact on protein profile, although influencing the intensity of peaks. Repeated freeze/thaw cycles (up to five) did not affect either the number or the intensity of the peaks. A comparison of the protein profile from eight different healthy individuals showed fairly consistent inter-subject similarities, along with between-subject differences, which were markedly dependent on the sex and the type of ProteinChip array used. The addition of a variety of denaturing agents improved the quality of the spectra with all the chips tested (CM10, Q10 and H50), but not with the copper-coated IMAC-30 chip. Finally, SPA matrix allowed to achieve a better performance of SELDI-TOF/MS spectrum, as compared with CHCA, regardless of the ProteinChip array used and even in the low m/z range (2500-10,000). In conclusion, we suggest that a careful choice of a number of pre-analytical and analytical conditions is required to accomplish and define a unifying protocol for the analysis of human urine by SELDI-TOF/MS, in physiological and in pathological states.

Entities:  

Mesh:

Year:  2007        PMID: 17613287     DOI: 10.1016/j.jchromb.2007.06.001

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  17 in total

Review 1.  Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies?

Authors:  Massimo Papale; Salvatore Di Paolo; Grazia Vocino; Maria Teresa Rocchetti; Loreto Gesualdo
Journal:  J Nephrol       Date:  2014-02-25       Impact factor: 3.902

Review 2.  Challenges for biomarker discovery in body fluids using SELDI-TOF-MS.

Authors:  Muriel De Bock; Dominique de Seny; Marie-Alice Meuwis; Jean-Paul Chapelle; Edouard Louis; Michel Malaise; Marie-Paule Merville; Marianne Fillet
Journal:  J Biomed Biotechnol       Date:  2009-12-06

3.  Biospecimen reporting for improved study quality (BRISQ).

Authors:  Helen M Moore; Andrea B Kelly; Scott D Jewell; Lisa M McShane; Douglas P Clark; Renata Greenspan; Daniel F Hayes; Pierre Hainaut; Paula Kim; Elizabeth Mansfield; Olga Potapova; Peter Riegman; Yaffa Rubinstein; Edward Seijo; Stella Somiari; Peter Watson; Heinz-Ulrich Weier; Claire Zhu; Jim Vaught
Journal:  J Proteome Res       Date:  2011-06-21       Impact factor: 4.466

4.  Biospecimen Reporting for Improved Study Quality.

Authors:  Helen M Moore; Andrea Kelly; Scott D Jewell; Lisa M McShane; Douglas P Clark; Renata Greenspan; Pierre Hainaut; Daniel F Hayes; Paula Kim; Elizabeth Mansfield; Olga Potapova; Peter Riegman; Yaffa Rubinstein; Edward Seijo; Stella Somiari; Peter Watson; Heinz-Ulrich Weier; Claire Zhu; Jim Vaught
Journal:  Biopreserv Biobank       Date:  2011-04       Impact factor: 2.300

5.  Profilin 1 is a potential biomarker for bladder cancer aggressiveness.

Authors:  Jerome Zoidakis; Manousos Makridakis; Panagiotis G Zerefos; Vasiliki Bitsika; Sergio Esteban; Maria Frantzi; Konstantinos Stravodimos; Nikolaos P Anagnou; Maria G Roubelakis; Marta Sanchez-Carbayo; Antonia Vlahou
Journal:  Mol Cell Proteomics       Date:  2011-12-08       Impact factor: 5.911

Review 6.  Before you analyze a human specimen, think quality, variability, and bias.

Authors:  Mark David Lim; Anthony Dickherber; Carolyn C Compton
Journal:  Anal Chem       Date:  2010-11-29       Impact factor: 6.986

7.  Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy.

Authors:  Maria Teresa Rocchetti; Massimo Papale; Anna Maria d'Apollo; Ida Valentina Suriano; Anna Maria Di Palma; Grazia Vocino; Eustacchio Montemurno; Leonarda Varraso; Giuseppe Grandaliano; Salvatore Di Paolo; Loreto Gesualdo
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

8.  Novel possibilities in the study of the salivary proteomic profile using SELDI-TOF/MS technology.

Authors:  Fatima Ardito; Donatella Perrone; Roberto Cocchi; Lucio Lo Russo; Alfredo DE Lillo; Giovanni Giannatempo; Lorenzo Lo Muzio
Journal:  Oncol Lett       Date:  2016-02-09       Impact factor: 2.967

9.  B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?

Authors:  Petra Richter; Markus Tost; Marcus Franz; Annelore Altendorf-Hofmann; Kerstin Junker; Laura Borsi; Dario Neri; Hartwig Kosmehl; Heiko Wunderlich; Alexander Berndt
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-27       Impact factor: 4.553

10.  Decreased urinary beta-defensin-1 expression as a biomarker of response to arsenic.

Authors:  Christine M Hegedus; Christine F Skibola; Marcella Warner; Danica R Skibola; David Alexander; Sophia Lim; Nygerma L Dangleben; Luoping Zhang; Michael Clark; Ruth M Pfeiffer; Craig Steinmaus; Allan H Smith; Martyn T Smith; Lee E Moore
Journal:  Toxicol Sci       Date:  2008-05-28       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.